BDX
Becton, Dickinson and Company
Price performance
Sep 18, 2026About
Company activity
33 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/06 | BDX | 8-K | BD Announces Third Fiscal Quarter 2026 Financial Results | — | — | — |
| 07/22 | BDX | 8-K | Dr. Michael Garrison to Retire from BD | — | — | — |
| 05/29 | BDX | 8-K | BD Resumes Shipment of ChloraPrep and PurPrep in the U.S. | — | — | — |
| 05/20 | BDX | 8-K | Becton Dickinson Subsidiary Issues €600M in Notes | — | — | — |
| 05/12 | BDX | 8-K | Becton, Dickinson and Company Announces New Debt Issuance | — | — | — |
| 05/07 | BDX | 8-K | BD Announces Second Fiscal Quarter Financial Results | — | — | — |
| 04/29 | BDX | 8-K | Becton, Dickinson Amends By-laws to Update Contested Election Notice Period | — | — | — |
| 04/09 | BDX | 8-K | Retirement of Executive Vice President Richard E. Byrd | — | — | — |
| 04/02 | BDX | 8-K | BD Announces Spin-Off of Biosciences and Diagnostics Solutions Business | — | — | — |
| 02/25 | BDX | 8-K | Becton, Dickinson Announces Early Tender Results and Upsizing of Tender Offers | — | — | — |
| 02/10 | BDX | 8-K | Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities | — | — | — |
| 02/09 | BDX | 8-K | BD Announces Q1 2026 Results and Finalizes Biosciences and Diagnostic Solutions Business Combination | — | — | — |
| 02/09 | BDX | 8-K | BD Completes Spin-Off of Biosciences and Diagnostic Solutions Business to Waters | — | — | — |
| 02/05 | BDX | 8-K | BD Announces Organizational Realignment into Five Segments | — | — | — |
| 02/05 | BDX | 8-K | Becton Dickinson Files for Preferred Stock Issuance in Spin-Off | — | — | — |
| 01/30 | BDX | 8-K | Becton, Dickinson Adopts New Executive Severance Plan and Amends Equity Compensation Plan | — | — | — |
| 01/06 | BDX | 8-K | BD Announces Temporary Trading Suspension in 401(k) Plan Due to Waters Transaction | — | — | — |
| 12/01/25 | BDX | 8-K | Becton, Dickinson Announces Appointment of New Board Members | — | — | — |
| 11/17/25 | BDX | 8-K | BD Announces Additions to Board of Directors | — | — | — |
| 11/06/25 | BDX | 8-K | BD Reports Fourth Fiscal Quarter 2025 Financial Results | — | — | — |
| 10/15/25 | BDX | 8-K | BD Announces Preliminary Revenue and CFO Transition | — | — | — |
| 09/17/25 | BDX | 8-K | BD Enters Third Amended Credit Agreement | — | — | — |
| 08/07/25 | BDX | 8-K | BD Announces Q3 2025 Financial Results and Raises Guidance | — | — | — |
| 07/14/25 | BDX | 8-K | BD to Combine Biosciences & Diagnostic Solutions Business with Waters in $17.5 Billion Reverse Morris Trust Transaction | — | — | — |
| 07/14/25 | BDX | 8-K | Becton, Dickinson and Company Announces Agreement to Combine Biosciences and Diagnostic Solutions Business with Waters Corporation | — | — | — |
| 06/16/25 | BDX | 8-K | Proposed Settlement of Stockholder Derivative Litigation | — | — | — |
| 05/02/25 | BDX | 8-K | Becton, Dickinson and Company Updates Corporate Governance By-laws | — | — | — |
| 05/01/25 | BDX | 8-K | BD Reports Strong Q2 Results and Updates Fiscal 2025 Guidance | — | — | — |
| 03/27/25 | BDX | 8-K | Becton Dickinson Appoints Gregory J. Hayes to Board of Directors | — | — | — |
| 02/05/25 | BDX | 8-K | BD Announces First Quarter Results and Plans to Separate Biosciences and Diagnostic Solutions | — | — | — |
| 01/31/25 | BDX | 8-K | BD Annual Meeting Voting Results Announced | — | — | — |
| 01/10/25 | BDX | 8-K | BD Appoints Pamela Spikner as New Chief Accounting Officer and Controller | — | — | — |
| 11/07/24 | BDX | 8-K | Becton Dickinson Reports Strong Q4 2024 Financial Results | — | — | — |
BDX filing record
Becton, Dickinson and Company (BDX): 33 8-K filings summarized, the most recent on Aug 6, 2026.
What the 8-K filings said
- Aug 6, 2026 · medium impact
On August 6, 2026, Becton, Dickinson and Company (BD) announced its financial results for the third fiscal quarter ending June 30, 2026. The company issued a press release with details on its performance, which is furnished as Exhibit 99.1 to this report. The press release includes non-GAAP financial measures and…
BD Announces Third Fiscal Quarter 2026 Financial Results - Jul 22, 2026 · high impact
On July 19, 2026, Dr. Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments at Becton, Dickinson and Company (BD), announced his intention to retire effective October 2, 2026. Dr. Garrison will remain in his role through the end of the fiscal year to…
Dr. Michael Garrison to Retire from BD - May 29, 2026 · high impact
On May 29, 2026, Becton, Dickinson and Company (BD) announced the resumption of shipment of ChloraPrep and PurPrep in the U.S. after conducting additional final release testing. The products were placed on ship hold on May 6, 2026, in response to a Warning Letter from the FDA for the El Paso manufacturing facility.…
BD Resumes Shipment of ChloraPrep and PurPrep in the U.S. - May 20, 2026 · medium impact
On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a subsidiary of Becton, Dickinson and Company, issued €600M in 3.855% Notes due 2033. The notes are fully guaranteed by Becton, Dickinson and Company. The company intends to use the proceeds to repay existing notes and for general corporate purposes.
Becton Dickinson Subsidiary Issues €600M in Notes - May 12, 2026 · medium impact
On May 11, 2026, Becton, Dickinson and Company, through its subsidiary Becton Dickinson Euro Finance S.à r.l., entered into an underwriting agreement for the issuance of €600,000,000 aggregate principal amount of 3.855% Euro Notes due 2033. The notes are fully and unconditionally guaranteed by BD. The net proceeds…
Becton, Dickinson and Company Announces New Debt Issuance
SEC filings in the last five years
- 74 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 8-K/A